Cargando…
Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
OBJECTIVES: We sought to confirm in very early rheumatoid arthritis (ERA) a much greater superiority (30%) of first-line etanercept+methotrexate (ETN+MTX) over treat-to-target MTX (MTX-TT) than previously reported in ERA (14%); and explore whether ETN following initial MTX secures a comparable respo...
Autores principales: | Emery, Paul, Horton, Sarah, Dumitru, Raluca Bianca, Naraghi, Kamran, van der Heijde, Désirée, Wakefield, Richard J, Hensor, Elizabeth M A, Buch, Maya H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147179/ https://www.ncbi.nlm.nih.gov/pubmed/31996367 http://dx.doi.org/10.1136/annrheumdis-2019-216539 |
Ejemplares similares
-
Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016) -
A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)
por: Dumitru, Raluca B., et al.
Publicado: (2016) -
Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission
por: Curtis, Jeffrey R., et al.
Publicado: (2021) -
Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
por: Matucci-Cerinic, Marco, et al.
Publicado: (2018) -
Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2016)